Phaseline

Companies › Immuneering

Immuneering: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Atebimetinib
MEK inhibitor
MAP2K1Phase 3Pancreatic CancerJun 2028
IMM-1-104
RAS/MAPK pathway inhibitor
–Phase 1Advanced Solid TumorJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05585320IMM-1-104Phase 1Advanced Solid TumorOncologyJun 2027
NCT07562152AtebimetinibPhase 3Pancreatic CancerOncologyJun 2028

From the company's SEC filings

Cash of $58m on 2026-09-30; operating cash outflow about $69m a year; runway about 10 months at that burn, to Aug 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

MAP2K1 (1)

Companies with the same targets

Roche AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma Pasithea Therapeutics Genfit Novartis Merck KGaA SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Nested Therapeutics

Companies built like this

Verastem Neonc Technologies Lantern Pharma Kura Oncology Inhibrx Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.